Technical Analysis for HBP - Helix BioPharma Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 20 DMA Support | Bullish | 2.63% | |
| 50 DMA Support | Bullish | 2.63% | |
| Hammer Candlestick | Bullish | 2.63% | |
| Outside Day | Range Expansion | 2.63% | |
| Gapped Up | Strength | 2.63% | |
| Crossed Above 20 DMA | Bullish | 2.63% | |
| Crossed Above 50 DMA | Bullish | 2.63% | |
| MACD Bullish Centerline Cross | Bullish | 2.63% |
| Alert | Time |
|---|---|
| Up 2% | about 18 hours ago |
| Up 1% | about 18 hours ago |
| 1.5x Volume Pace | about 18 hours ago |
| 50 DMA Support | 1 day ago |
| Down 1 ATR | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 2024-04-16
Helix BioPharma Corp. Description
Helix BioPharma Corp. is an immuno-oncology company, which specializes in the field of cancer therapy. The Company is developing products for the prevention and treatment of cancer based on its technologies. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. The Company's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Manufacturing Medicine Pharma Clinic Drug Cancer Drugs Medical Specialties Therapy Oncology Tumor Lung Cancer Treatment Of Cancer Antibody Cancer Immunotherapy Non Small Cell Lung Cancer Product Development Monoclonal Antibodies Treatment Of Non Small Cell Lung Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.26 |
| 52 Week Low | 0.15 |
| Average Volume | 16,471 |
| 200-Day Moving Average | 0.208 |
| 50-Day Moving Average | 0.185 |
| 20-Day Moving Average | 0.186 |
| 10-Day Moving Average | 0.187 |
| Average True Range | 0.013 |
| RSI (14) | 53.49 |
| ADX | 19.6 |
| +DI | 36.415 |
| -DI | 39.853 |
| Chandelier Exit (Long, 3 ATRs) | 0.172 |
| Chandelier Exit (Short, 3 ATRs) | 0.198 |
| Upper Bollinger Bands | 0.202 |
| Lower Bollinger Band | 0.169 |
| Percent B (%b) | 0.79 |
| BandWidth | 17.682 |
| MACD Line | 0.001 |
| MACD Signal Line | 0.000 |
| MACD Histogram | 0.0011 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.195 | ||||
| Resistance 3 (R3) | 0.195 | 0.195 | 0.195 | ||
| Resistance 2 (R2) | 0.195 | 0.195 | 0.195 | 0.195 | |
| Resistance 1 (R1) | 0.195 | 0.195 | 0.195 | 0.195 | 0.195 |
| Pivot Point | 0.195 | 0.195 | 0.195 | 0.195 | 0.195 |
| Support 1 (S1) | 0.195 | 0.195 | 0.195 | 0.195 | 0.195 |
| Support 2 (S2) | 0.195 | 0.195 | 0.195 | 0.195 | |
| Support 3 (S3) | 0.195 | 0.195 | 0.195 | ||
| Support 4 (S4) | 0.195 |
